Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice

Journal of Virology

Volumn 85, Issue 5, 2011, Pages 1994-2003

  Zlatkovic, Juergen ^a   Stiasny, Karin ^a   Heinz, Franz X ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; SOLUBLE PROTEIN E; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ISOLATION; VIRION; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; HUMANS; MICE; MICE, INBRED C57BL; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

MUS; WEST NILE VIRUS;

EID: 79551707739     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01886-10     Document Type: Article

References (66)

1. Alka, K. Bharati, Y. P. Malik, and S. Vrati. 2007. Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. Med. Microbiol. Immunol. 196:227-231.
2. Babu, J. P., et al. 2008. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 26:4655-4663.
3. Beasley, D. W., and A. D. Barrett. 2002. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76:13097-13100.
4. Beasley, D. W., et al. 2004. Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. J. Clin. Microbiol. 42:2759-2765.
5. Bernardo, L., et al. 2008. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch. Virol. 153:849-854.
6. Bhardwaj, S., M. Holbrook, R. E. Shope, A. D. Barrett, and S. J. Watowich. 2001. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J. Virol. 75:4002-4007.
7. Brady, S. T. 2005. Ph.D. thesis. University of Oxford, Oxford, United Kingdom.
8. Chen, S., et al. 2007. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 26:361-367. (Pubitemid 46981691)
9. Cherrier, M. V., et al. 2009. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 28:3269-3276.
10. Chu, J. J., et al. 2005. Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 86:405-412.
11. Crill, W. D., and G. J. Chang. 2004. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78:13975-13986.
12. Crill, W. D., H. R. Hughes, M. J. Delorey, and G. J. Chang. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:e4991.
13. Diamond, M. S., T. C. Pierson, and D. H. Fremont. 2008. The structural immunology of antibody protection against West Nile virus. Immunol. Rev. 225:212-225.
14. Dormitzer, P. R., J. B. Ulmer, and R. Rappuoli. 2008. Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26:659-667.
15. Fauquet, C. M., M. A. Mayo, J. Maniloff, U. Desselberger, and L. A. Ball. 2005. Virus taxonomy. Elsevier Inc., San Diego, CA.
16. Forsell, M. N., W. R. Schief, and R. T. Wyatt. 2009. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr. Opin. HIV AIDS 4:380-387.
17. Gromowski, G. D., N. D. Barrett, and A. D. Barrett. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828-8837.
18. Gubler, D. J. 2007. The continuing spread of West Nile virus in the western hemisphere. Clin. Infect. Dis. 45:1039-1046.
19. Guzman, M. G., L. Hermida, L. Bernardo, R. Ramirez, and G. Guillen. 2010. Domain III of the envelope protein as a dengue vaccine target. Expert Rev. Vaccines 9:137-147.
20. Heinz, F. X., et al. 1995. Recombinant and virion-derived soluble and particulate immunogens for vaccination against tick-borne encephalitis. Vaccine 13:1636-1642. (Pubitemid 26014866)
21. Heinz, F. X., R. Berger, W. Tuma, and C. Kunz. 1983. A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology 126:525-537. (Pubitemid 13089876)
22. Heinz, F. X., and C. Kunz. 1981. Homogeneity of the structural glycoprotein from European isolates of tick-borne encephalitis virus: comparison with other flaviviruses. J. Gen. Virol. 57:263-274.
23. Hermida, L., et al. 2004. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 115:41-49. (Pubitemid 37500961)
24. Hjelm, F., F. Carlsson, A. Getahun, and B. Heyman. 2006. Antibody-mediated regulation of the immune response. Scand. J. Immunol. 64:177-184.
25. Junjhon, J., et al. 2010. Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles. J. Virol. 84:8353-8358.
26. Kanai, R., et al. 2006. Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes. J. Virol. 80:11000-11008. (Pubitemid 44706541)
27. Kaufmann, B., et al. 2006. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 103: 12400-12404.
28. Khanam, S., B. Etemad, N. Khanna, and S. Swaminathan. 2006. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am. J. Trop. Med. Hyg. 74:266-277.
29. Khanam, S., N. Khanna, and S. Swaminathan. 2006. Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24:6513-6525. (Pubitemid 44511859)
30. Kiermayr, S., K. Stiasny, and F. X. Heinz. 2009. Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E. J. Virol. 83:8482-8491.
31. Kuhn, R. J., et al. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725. (Pubitemid 34241430)
32. Lai, C. Y., et al. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 82:6631-6643.
33. Lee, J. W., J. J. Chu, and M. L. Ng. 2006. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. J. Biol. Chem. 281:1352-1360.
34. Lindenbach, B. D., H.-J. Thiel, and C. M. Rice. 2007. Flaviviridae: the viruses and their replication, p. 1101-1152. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
35. Lok, S. M., et al. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-317.
36. Mason, P. W., et al. 1989. Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J. Gen. Virol. 70(Pt 8):2037-2049.
37. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 100:6986-6991.
38. Modis, Y., S. Ogata, D. Clements, and S. C. Harrison. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79:1223-1231.
39. Mukhopadhyay, S., B. S. Kim, P. R. Chipman, M. G. Rossmann, and R. J. Kuhn. 2003. Structure of West Nile virus. Science 302:248.
40. Nelson, S., et al. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4:e1000060.
41. Nybakken, G. E., C. A. Nelson, B. R. Chen, M. S. Diamond, and D. H. Fremont. 2006. Crystal structure of the West Nile virus envelope glycoprotein. J. Virol. 80:11467-11474.
42. Nybakken, G. E., et al. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437:764-769. (Pubitemid 41486548)
43. Oliphant, T., et al. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
44. Oliphant, T., et al. 2007. Induction of epitope-specific neutralizing antibodies against West Nile virus. J. Virol. 81:11828-11839.
45. Oliphant, T., et al. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 80:12149-12159.
46. Peeters, C. C., et al. 1991. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:3504-3510.
47. Pierson, T. C., and M. S. Diamond. 2008. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10:e12.
48. Pierson, T. C., D. H. Fremont, R. J. Kuhn, and M. S. Diamond. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229-238.
49. Plotkin, S. A., W. A. Orenstein, and P. A. Offit. 2008. Vaccines, 5th ed. W. B. Saunders, Philadelphia, PA.
50. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375:291-298.
51. Roehrig, J. T. 2003. Antigenic structure of flavivirus proteins. Adv. Virus Res. 59:141-175.
52. Roehrig, J. T., R. A. Bolin, and R. G. Kelly. 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317-328.
53. Sanchez, M. D., et al. 2007. The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359:336-348. (Pubitemid 46290659)
54. Simmons, M., K. R. Porter, C. G. Hayes, D. W. Vaughn, and R. Putnak. 2006. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J. Virol. 80:9577-9585. (Pubitemid 44435632)
55. Spohn, G., et al. 2010. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol. J. 7:146.
56. Steel, J., et al. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1:e00018-10.
57. Stiasny, K., H. Holzmann, and F. X. Heinz. 2009. Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs. Vaccine 27:7021-7026.
58. Stiasny, K., S. Kiermayr, H. Holzmann, and F. X. Heinz. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80:9557-9568.
59. Sukupolvi-Petty, S., et al. 2007. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816-12826. (Pubitemid 350156919)
60. Throsby, M., et al. 2006. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J. Virol. 80:6982-6992. (Pubitemid 44025197)
61. Valdes, I., et al. 2010. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int. J. Infect. Dis. 14:e377-e383.
62. Virgin, H. W., and B. D. Walker. 2010. Immunology and the elusive AIDS vaccine. Nature 464:224-231.
63. Wahala, W. M., A. A. Kraus, L. B. Haymore, M. A. Accavitti-Loper, and A. M. de Silva. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103-113.
64. Wu, K. P., et al. 2003. Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. J. Biol. Chem. 278:46007-46013.
65. Wu, S. C., C. H. Yu, C. W. Lin, and I. M. Chu. 2003. The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine 21:2516-2522.
66. Zhang, W., et al. 2003. Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat. Struct. Biol. 10:907-912.